CFHR3 is a potential novel biomarker for hepatocellular carcinoma

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ADAMTSL4, a Secreted Glycoprotein, Is a Novel Immune-Related Biomarker for Primary Glioblastoma Multiforme

(2019) Zheng Zhao et al.   DISEASE MARKERS

Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity

(2019) Elena E. Tchekneva et al.   Journal for ImmunoTherapy of Cancer

The complement factor H (CFH) and its related protein 2 (CFHR2) mediating immune response in large yellow croaker Larimichthys crocea

(2018) Pengzhi Qi et al.   DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY

High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B

(2018) Richard B. Pouw et al.   Frontiers in Immunology

The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma

(2018) Sung Hwan Cho et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

SAC3D1: a novel prognostic marker in hepatocellular carcinoma

(2018) Myoung-Eun Han et al.   Scientific Reports

HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas

(2018) Qiuyu Lian et al.   GENOMICS PROTEOMICS & BIOINFORMATICS

Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model

(2017) Guangfu Li et al.   JOURNAL OF HEPATOLOGY

Deletion Variants ofCFHR1andCFHR3Associate with Mesangial Immune Deposits but Not with Progression of IgA Nephropathy

(2017) Perrine Jullien et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy

(2017) Shambhuprasad K. Togarsimalemath et al.   KIDNEY INTERNATIONAL

Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors

(2017) Nathan O. Siemers et al.   PLoS One

Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1

(2016) Hyang Sook Seol et al.   CANCER LETTERS

Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

(2016) Jordi Bruix et al.   GASTROENTEROLOGY

IL-6 and IL-8 enhance factor H binding to the cell membranes

(2016) SYLWIA POPEK et al.   Molecular Medicine Reports

Mechanisms and pathways of innate immune activation and regulation in health and cancer

(2015) Jun Cui et al.   Human Vaccines & Immunotherapeutics

Retinoblastoma protein potentiates the innate immune response in hepatocytes: Significance for hepatocellular carcinoma

(2014) Jack Hutcheson et al.   HEPATOLOGY

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Dimerization of complement factor H-related proteins modulates complement activation in vivo

(2013) E. Goicoechea de Jorge et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inferring tumour purity and stromal and immune cell admixture from expression data

(2013) Kosuke Yoshihara et al.   Nature Communications

Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate

(2012) Wei Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Hepatocellular carcinoma

(2012) Alejandro Forner et al.   LANCET

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Association of Genetic Variants in Complement Factor H and Factor H-Related Genes with Systemic Lupus Erythematosus Susceptibility

(2011) Jian Zhao et al.   PLoS Genetics

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

International network of cancer genome projects

(2010) Thomas J. Hudson (Chairperson) et al.   NATURE